Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.

What is mazdutide?

Mazdutide (also known as IBI362 or LY3305677) is an investigational peptide that activates two receptors at once — the GLP-1 receptor and the glucagon receptor (a “dual agonist”). This combined mechanism is studied for effects on appetite and energy expenditure (Ji et al., 2022).

What the clinical research examined

In a randomized, placebo-controlled phase 1b multiple-ascending-dose trial in Chinese adults with overweight or obesity, once-weekly mazdutide was well tolerated, with adverse events that were mild-to-moderate and mostly gastrointestinal. Over 12 weeks, the 9 mg dose was associated with a mean body-weight reduction of about 11.7% versus 1.8% with placebo, with additional reductions in waist circumference and BMI (Ji et al., 2022). In a broader network meta-analysis of GLP-1 receptor agonists and polyagonists, dual and triple receptor agonists were generally more effective for weight reduction than single GLP-1 agonists (Xie et al., 2024).

How it is thought to work

By engaging both GLP-1 and glucagon receptors, mazdutide is studied for complementary effects on satiety and metabolic rate — part of a wider research area on incretin-based polyagonists (Ji et al., 2022).

The limits and important context

  • Mazdutide is investigational: studied in clinical trials but not an approved medicine, and its long-term safety and outcomes are still being established.
  • Clinical-trial data come from supervised settings and do not translate to unsupervised use. This material is supplied for laboratory research use only.

References

According to PubMed:

  1. Ji L, et al. Safety and efficacy of GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: phase 1b trial. EClinicalMedicine. 2022. doi:10.1016/j.eclinm.2022.101691
  2. Xie Z, et al. Seven GLP-1 receptor agonists and polyagonists for weight loss: network meta-analysis. Metabolism. 2024. doi:10.1016/j.metabol.2024.156038
Disclaimer: This content is educational only and reflects published research. It is not medical advice and makes no claim regarding the diagnosis, treatment, cure, or prevention of any disease. Products referenced are for in-vitro laboratory research use only (RUO); they are not for human or veterinary use. Compounds in clinical trials are not approved for general use; that status does not apply to the research material sold here.

Related Posts